REGN


Regeneron Prices $1.25B Public Offering; Analyst Cautious On Valuation

Regeneron Pharmaceuticals (REGN) has now announced the pricing of an underwritten offering of $1.250 billion aggregate principal amount of senior unsecured notes due …

Regeneron: Covid-19 Antibody Combo Prevents & Treats Disease In Animals

Regeneron Pharmaceuticals Inc (REGN) has revealed that its investigational COVID-19 antibody drug combination REGN-COV2 both prevented and treated the disease in monkeys and …

Regeneron Signs $450M Contract With U.S. Government For Covid-19 Therapy  

Regeneron Pharmaceuticals, Inc (REGN) announced on Tuesday that it has won a $450 million contract with the U.S government to manufacture and supply …

Sanofi, Regeneron Win China Approval For Dupixent Dermatitis Drug

French drugmaker Sanofi (SNYNF) has received regulatory approval in China for its Dupixent drug, which it is developing together with Regeneron Pharmaceuticals, Inc …

Regeneron Starts Human Clinical Trials Of Covid-19 Antibody Cocktail

Regeneron Pharmaceuticals, Inc (REGN) said Thursday it started the first human clinical trial of REGN-COV2, its investigational dual antibody cocktail for the prevention …

Sanofi Seeks Growth Strategy For Dupixent Drug To Meet €10B Peak Sales Target

French drugmaker Sanofi (SNYNF) said it is exploring additional growth opportunities for its Dupixent drug, which it is developing together with Regeneron Pharmaceuticals, …

Regeneron, Intellia Expand Partnership To Develop Hemophilia Treatments

Regeneron Pharmaceuticals, Inc (REGN) and Intellia Therapeutics, Inc. (NTLA) announced an expansion of their partnership to jointly develop potential products for the treatment of hemophilia …

Regeneron, Sanofi Get FDA Nod For Dupixent Treatment In Children

Drug companies Regeneron Pharmaceuticals, Inc (REGN) and Sanofi announced that the U.S.

Regeneron Announces Secondary Offering Pricing At $515/Share

Regeneron Pharma (REGN) has now announced the pricing of the underwritten public secondary offering of 11,831,496 shares of its common stock held by …

Regeneron and Sanofi’s Dupixent Shows ‘Positive’ Trial Data, Meets Co-Primary Endpoints

Drug companies Regeneron Pharmaceuticals, Inc (REGN) and Sanofi announced that results for their Dupixent drug used for the treatment of patients with swallowing …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts